Halberd to bid on Additional Federal Contracts with the Federal Government Jackson Center, PA, January 5, 2022 – Halberd Corporation (OTC PINK:HALB) is now registered with the Federal Government’s System for Award Management allowing Halberd to bid on Federal contracts and conduct business with the Federal government in the areas of Research and Development in ...
Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid Jackson Center, PA, December 20, 2021 – Halberd Corporation (OTC PINK:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd has also completed confirmatory tests on the elimination of all the previously tested cytokines (see table below). Interleukin-2 ...
Jackson Center, PA, December 15, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-12 is a pro-inflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimer’s Disease or mild cognitive impairment. Halberd’s demonstrated ability to control the ...
Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease. Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous ...
Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation. TNF-alpha is an inflammatory cytokine ...
Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease Jackson Center, PA, November 22, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd’s patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated ...
Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional patent application on this treatment method. Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...
Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication ...
Jackson Center, PA, October 25, 2021 – Halberd Corporation (OTC-PINK: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity. Removal of these obesity-related target elements would reduce or eliminate ...
Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity. Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in ...